The initial treatment benefits of Soliris (eculizumab) were maintained after people with generalized myasthenia gravis (gMG) switched over to Ultomiris (ravulizumab-cwvz), a small real-world study confirmed. Most patients who completed a survey almost six months after switching said they preferred Ultomiris due to treatment convenience, lower frequency…
News
Butyric acid from gut bacteria, or supplementation with its salt form butyrate, could become potential treatments for myasthenia gravis (MG) by working to restore the function of immune cells that limit the production of disease-causing antibodies. That’s according to the findings of a new study in human cells and…
The 2024 National Patient Conference by the Myasthenia Gravis Foundation of America (MGFA) brought together more than 400 members of the myasthenia gravis (MG) community this week to educate participants about how to better manage their disease and raise awareness about treatments and clinical studies. “We are so…
Treatment with an oral version of salbutamol, the active ingredient of medications used for asthma and other respiratory conditions, may help ease symptoms in some people with MuSK-positive myasthenia gravis (MG), a small study reports. The study was published as a letter to the editor, titled “…
Many of the adults with generalized myasthenia gravis (gMG) who took part in ADAPT, a Phase 3 clinical study of Vyvgart (efgartigimod), and its open-label extension, ADAPT+, experienced minimal or no symptoms and a quality of life closer to that of healthy adults. While Vyvgart is approved to…
Ultomiris (ravulizumab) continues to be well tolerated and to keep symptoms of generalized myasthenia gravis (gMG) under control when used for more than three years, according to a final analysis of data from an open-label extension of the Phase 3 CHAMPION-MG trial. The data were presented by Tuan…
People with myasthenia gravis (MG) — particularly those with more severe symptoms — are significantly hindered both in their ability to work and to engage in activities of daily living, a survey study reported. The impact of these impairments ranged from 13% to 40% across work time missed, as…
A young girl who showed unusual symptoms of ocular myasthenia gravis — persistent upper eyelid droopiness and outward deviation of the right eye — saw her symptoms ease after she received standard treatment, a case report shows. “This case emphasizes the diverse presentation of MG in ophthalmology, with ocular…
The U.S. Food and Drug Administration (FDA) has given the green light to Iaso Bio to start clinical testing of its BCMA CAR T-cell therapy equecabtagene autoleucel, known as Eque-cel for short, in people with generalized myasthenia gravis (gMG) who live in the U.S. Clearance of the company’s request,…
No significant differences in clinical outcomes or quality of life were observed between myasthenia gravis (MG) patients treated with azathioprine or mycophenolate mofetil (MMF), results from the PROMISE-MG observational study show. While “more comparative effectiveness studies are required,” the findings “provide important information for the clinical management…
Recent Posts
- I learn asking for help means choosing not to do everything the hard way
- The thought of not having myasthenia gravis does not bring me peace
- Zilbrysq’s safety, efficacy in real-world study mirror trial findings
- Vyvgart may fill gap in medications for juvenile MG: Real-world study
- Antibody levels may help track disease severity in children with MG